Healthcare utilization and costs in adults with type 2 diabetes treated with first or second-generation basal insulins in England
Authors' conclusion
These findings suggest that Gla-300 may offer clinical and economic benefits by reducing hypoglycemia incidents and lowering healthcare costs compared with first-generation BI.
Study context
- Population
- Adults with T2D who initiated a first-generation basal insulin (BI) and switched to another first-generation or a second-generation BI, 1 July 2014–31 March 2021, England; mean (SD) age 62.45 (13.59) years
- Participants
- 13,975 adults
- Exposure
- Switch to Gla-300 or degludec vs switch to another first-generation BI
- First-generation BIn = 5,654reference
- Gla-300n = 4,737
- Degludecn = 3,584
- Outcome
- Healthcare resource utilization (HCRU) and costs
- Follow-up
- From index date
Methodological detailscomparative, observational, propensity score weighting, Clinical Practice Research Datalink (CPRD) Aurum linked to Hospital Episode Statistics
- Comparative
- Observational
- Propensity score weighting
- CPRD Aurum linked to Hospital Episode Statistics
Main finding
As reported in the abstract
Hypoglycemia-related healthcare · follow-up
Incidence rate ratio
0.41
P < 0.001
Gla-300 vs First-generation BI · 9.1% vs 16.4%
Incidence rate ratio
0.51
P < 0.001
Gla-300 vs Degludec · 9.2% vs 11.7%
Observational data: associations, not effects.
Further findings
Follow-up time
Total direct costs · follow-up
- Diabetes-related total direct costs lower with Gla-300 vs first-generation BI
- 17%
- DKA-related total direct costs lower with Gla-300 vs degludec
- 60%
Original publication
Healthcare utilization and costs in adults with type 2 diabetes treated with first or second-generation basal insulins in England. BMJ Open Diabetes Res Care. Published 28 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →